Brain waves could help paralyzed patients move again

We are developing a non-invasive brain-computer interface (BCI) system that uses EEG (electroencephalography) to detect movement intention in paralyzed patients and translates those signals to spinal cord stimulators, enabling partial restoration of movement. The technology bridges the gap between intact brain signals and compromised spinal pathways, offering hope for individuals with spinal cord injuries. Our solution leverages existing EEG hardware combined with proprietary signal processing algorithms and spinal stimulation devices to create a closed-loop system that turns thought into action without invasive brain surgery.

Positioned as the first clinically viable, non-invasive BCI system specifically designed for spinal cord injury rehabilitation. Unlike invasive implants, our EEG-based approach reduces surgical risks, lowers costs, and accelerates patient adoption. We target the gap between consumer EEG devices (which lack medical precision) and invasive BCIs (which carry surgical risks). Key value propositions: accessibility, safety, and rapid deployment in rehabilitation settings.

• High-density EEG cap with dry electrodes for comfortable, long-term wear
• Real-time intention decoding algorithm that identifies movement attempts from brain waves
• Integrated interface with FDA-approved spinal cord stimulators
• Machine learning adaptive system that improves accuracy with patient use
• Comprehensive safety monitoring and fail-safe mechanisms
• Patient training software with gamified rehabilitation exercises

Primary competitors: 1) Invasive BCIs like Neuralink (estimated $10,500 per implant) and Blackrock Neurotech (MoveAgain system with FDA Breakthrough designation) – both require brain surgery. 2) Non-invasive consumer EEG companies like EMOTIV and NeuroSky – lack clinical validation. 3) Traditional spinal stimulation devices (Medtronic, Boston Scientific) – don't integrate brain signals. Our differentiation: non-invasive clinical-grade system specifically designed for spinal injury rehabilitation, balancing efficacy with safety.

B2B medical device model: sell system packages to rehabilitation hospitals and specialty clinics. Revenue streams: 1) Hardware sales (EEG caps, processing units), 2) Annual software subscription for algorithm updates and analytics, 3) Professional training and implementation services. Target FDA clearance as a Class II medical device. Pursue insurance reimbursement through Medicare/private payers. Long-term: partnership with established spinal stimulator manufacturers for integrated solutions.